RT Journal Article
T1 Document of revision and updating of medication overuse headache (MOH).
T2 Documento de revisión y actualización de la cefalea por uso excesivo de medicación (CUEM).
A1 González-Oria, C
A1 Belvís, R
A1 Cuadrado, M L
A1 Díaz-Insa, S
A1 Guerrero-Peral, A L
A1 Huerta, M
A1 Irimia, P
A1 Láinez, J M
A1 Latorre, G
A1 Leira, R
A1 Oterino, A
A1 Pascual, J
A1 Porta-Etessam, J
A1 Pozo-Rosich, P
A1 Sánchez Del Río, M
A1 Santos-Lasaosa, S
K1 Cefalea con uso excesivo de medicación
K1 Deshabituación
K1 Detoxification
K1 Ergot derivatives
K1 Ergóticos
K1 Medication overuse headache
K1 Opioides
K1 Opioids
K1 Preventive treatment
K1 Tratamiento preventivo
K1 Triptanes
K1 Triptans
AB Medication overuse headache is a secondary headache in which the regular or frequent use of analgesics can increase the frequency of the episodes, causing the transition from episodic to chronic headache. The prevalence of medication overuse headache is approximately 1-2%, with higher rates among women aged 30-50 years and with comorbid psychiatric disorders such as depression or anxiety, or other chronic pain disorders. It is important to be familiar with the management of this disease. To this end, the Spanish Society of Neurology's Headache Study Group has prepared a consensus document addressing this disorder. These guidelines were prepared by a group of neurologists specialising in headache after a systematic literature review and provides consensus recommendations on the proper management and treatment of medication overuse headache. The treatment of medication overuse headache is often complex, and is based on 4 fundamental pillars: education and information about the condition, preventive treatment, discontinuation of the drug being overused, and treatment for withdrawal symptoms. Follow-up of patients at risk of recurrence is important. We hope that this document will be useful in daily clinical practice and that it will update and improve understanding of medication overuse headache management.
YR 2020
FD 2020-09-09
LK http://hdl.handle.net/10668/16245
UL http://hdl.handle.net/10668/16245
LA en
LA es
DS RISalud
RD May 9, 2025